Estrella Immunopharma, Inc., was incorporated in Delaware on January 6, 2021. The Company is a preclinical stage biopharmaceutical company developing CD19 and CD22 targeted ARTEMIS T cell therapies with the ability to address the therapeutic challenges of patients with blood cancer and solid tumors. The company's mission is to harness the evolutionary power of the human immune system to transform the lives of cancer patients. To accomplish this mission, the company's lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The company is also developing EB104, which also utilizes Eureka's ARTEMIS technology, not only for CD19, but also for CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. 

ESLA

ESLA Profile